Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full U.S. share.Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.T&Cs apply
Kiniksa Pharmaceuticals International Plc
About KNSA
Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Its portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. Its ARCALYST is used for the treatment of recurrent pericarditis and reduces the risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist. Its other portfolio includes KPL-387, KPL-1161, Abiprubart, and Mavrilimumab. Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha.
Find out what a historical investment in Kiniksa Pharmaceuticals International Plc would be worth today using our KNSA stock calculator.
Market Capitalisation
$4.35B
Price-earnings ratio
-
Dividend yield
0.00%
Volume
471.52K
High today
$58.56
Low today
$56.22
Open price
$58.00
52-week high
$59.87
52-week low
$24.85
Ready to start your investing journey with Stake?
Open an accountHow do I buy KNSA shares in Australia?
Buying KNSA shares in Australia can be done through an online investing platform, such as Stake. Follow the simple steps below to start investing in Kiniksa Pharmaceuticals International Plc in minutes.
- Sign up with some I.D. and zero paperwork
- Add funds to your account
- Make your first investment in KNSA
What is the ticker symbol of Kiniksa Pharmaceuticals International Plc?
The ticker symbol for Kiniksa Pharmaceuticals International Plc is KNSA.
How much is one share of KNSA?
One share of KNSA is valued at $56.31 as of 17 May 2026.
What is the market capitalisation of Kiniksa Pharmaceuticals International Plc KNSA?
As of 17 May 2026 Kiniksa Pharmaceuticals International Plc has a market cap of $4.35B.
What is the P/E ratio of KNSA?
The Price to Earnings ratio of KNSA is 64.56.
What is the Earnings Per Share of KNSA?
The Earnings Per Share of KNSA is $0.91.
What is the 52-week high for Kiniksa Pharmaceuticals International Plc stock?
The Kiniksa Pharmaceuticals International Plc 52-week high stock price is $59.87.
What is the 52-week low for Kiniksa Pharmaceuticals International Plc stock?
The Kiniksa Pharmaceuticals International Plc 52-week low stock price is $24.85.
Can I buy KNSA shares through Stake, an investing platform like CommSec, Selfwealth or Superhero?
Yes, the Stake investing platform allows you to buy KNSA shares and over 12,000 more stocks and ETFs across the ASX and Wall St.
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in KNSA on Stake
- Buy KNSA from US$3 brokerage
- Invest in 9,500+ U.S. stocks and ETFs
- Own a slice of KNSA from only US$10 with fractional shares
Stock shown for demonstrative purposes only. US$3 brokerage up to US$30,000.
KNSA related stocks